Inovio Pharmaceuticals Faces Class Action Lawsuit After 24% Stock Plunge

Key Facts

1Inovio Pharmaceuticals (INO) shares declined 24% after an FDA review classification revealed an alleged regulatory setback.

2Levi & Korsinsky, LLP announced a securities class action lawsuit alleging misrepresentations about regulatory pathway eligibility.

3Investors have until April 7, 2026, to seek lead plaintiff status in the pending lawsuit.

Inovio Pharmaceuticals (INO) shares experienced a significant 24% decline following an FDA review classification that revealed an unexpected regulatory setback. In response to the price collapse, the law firm Levi & Korsinsky, LLP has filed a securities class action lawsuit against the company. The lawsuit alleges that Inovio made misrepresentations regarding its eligibility for specific regulatory pathways, thereby misleading the investment community. Investors who suffered losses now have until April 7, 2026, to apply for lead plaintiff status in the ongoing legal proceedings. This regulatory hurdle and subsequent litigation have cast a shadow over the company's immediate operational outlook and management's transparency. Market analysts suggest that the combination of legal pressure and FDA scrutiny could weigh heavily on the stock's performance in the near to medium term.